| Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread PP Wong, F Demircioglu, E Ghazaly, W Alrawashdeh, MRL Stratford, ... Cancer cell 27 (1), 123-137, 2015 | 212 | 2015 |
| Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development M Slusarczyk, MH Lopez, J Balzarini, M Mason, WG Jiang, S Blagden, ... Journal of medicinal chemistry 57 (4), 1531-1542, 2014 | 191 | 2014 |
| Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo F Miraki-Moud, E Ghazaly, L Ariza-McNaughton, KA Hodby, A Clear, ... Blood, The Journal of the American Society of Hematology 125 (26), 4060-4068, 2015 | 157 | 2015 |
| Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging MD Allen, P Luong, C Hudson, J Leyton, B Delage, E Ghazaly, R Cutts, ... Cancer research 74 (3), 896-907, 2014 | 133 | 2014 |
| The European medicines agency review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B‐cell lymphoma S Ali, R Kjeken, C Niederlaender, G Markey, TS Saunders, M Opsata, ... The oncologist 25 (2), e321-e327, 2020 | 127 | 2020 |
| Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism B Bilanges, S Alliouachene, W Pearce, D Morelli, G Szabadkai, YL Chung, ... Nature communications 8 (1), 1804, 2017 | 69 | 2017 |
| Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1 M Locke, E Ghazaly, MO Freitas, M Mitsinga, L Lattanzio, CL Nigro, ... Cell reports 16 (6), 1604-1613, 2016 | 50 | 2016 |
| A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP J Perry, E Ghazaly, C Kitromilidou, EH McGrowder, S Joel, T Powles Molecular cancer therapeutics 9 (12), 3322-3329, 2010 | 45 | 2010 |
| Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study SP Blagden, I Rizzuto, P Suppiah, D O’Shea, M Patel, L Spiers, ... British journal of cancer 119 (7), 815-822, 2018 | 39 | 2018 |
| Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study NKA Van Eijkelenburg, M Rasche, E Ghazaly, MN Dworzak, T Klingebiel, ... haematologica 103 (9), 1484, 2018 | 33 | 2018 |
| Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer C Walsh, JJ Bonner, TN Johnson, S Neuhoff, EA Ghazaly, JG Gribben, ... British journal of clinical pharmacology 81 (5), 989-998, 2016 | 29 | 2016 |
| Physiologically based pharmacokinetics model in pregnancy: a regulatory perspective on model evaluation P Coppola, E Kerwash, S Cole Frontiers in Pediatrics 9, 687978, 2021 | 28 | 2021 |
| Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole AM Abdel‐tawab, M Bradley, EA Ghazaly, J Horton, M El‐Setouhy British journal of clinical pharmacology 68 (5), 737-742, 2009 | 26 | 2009 |
| Pharmacological factors affecting accumulation of gemcitabine’s active metabolite, gemcitabine triphosphate I Rizzuto, E Ghazaly, GJ Peters Pharmacogenomics 18 (9), 911-925, 2017 | 23 | 2017 |
| BIOV-111 a European Phase II Trial of Clofarabine (Evoltra®) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia. P Kearns, G Michel, B Nelken, S Joel, E Al-Ghazaly, A Beishuizen, ... Blood 108 (11), 1859-1859, 2006 | 19 | 2006 |
| Commentary on the MID3 good practices paper E Manolis, J Brogren, S Cole, JL Hay, A Nordmark, KE Karlsson, F Lentz, ... CPT: Pharmacometrics & Systems Pharmacology 6 (7), 416-417, 2017 | 18 | 2017 |
| A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates S Cole, E Kerwash, A Andersson Drug Metabolism and Pharmacokinetics 35 (1), 2-11, 2020 | 17 | 2020 |
| Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate LS Moniz, S Surinova, E Ghazaly, LG Velasco, S Haider, ... Scientific Reports 7 (1), 39985, 2017 | 17 | 2017 |
| A phase Ib study of NUC‐1031 in combination with cisplatin for the first‐line treatment of patients with advanced biliary tract cancer (ABC‐08) MG McNamara, J Bridgewater, DH Palmer, O Faluyi, H Wasan, A Patel, ... The oncologist 26 (4), e669-e678, 2021 | 16 | 2021 |
| Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes A Marshall, J Kasturiarachchi, P Datta, Y Guo, E Deltcheva, C James, ... Scientific reports 10 (1), 19390, 2020 | 12 | 2020 |
